AU2001239551B8 - Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof - Google Patents

Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof Download PDF

Info

Publication number
AU2001239551B8
AU2001239551B8 AU2001239551A AU2001239551A AU2001239551B8 AU 2001239551 B8 AU2001239551 B8 AU 2001239551B8 AU 2001239551 A AU2001239551 A AU 2001239551A AU 2001239551 A AU2001239551 A AU 2001239551A AU 2001239551 B8 AU2001239551 B8 AU 2001239551B8
Authority
AU
Australia
Prior art keywords
keto
prostaglandin compound
compound
prostaglandin
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001239551A
Other languages
English (en)
Other versions
AU2001239551B2 (en
AU2001239551A1 (en
Inventor
Yukihiko Mashima
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of AU2001239551A1 publication Critical patent/AU2001239551A1/en
Publication of AU2001239551B2 publication Critical patent/AU2001239551B2/en
Application granted granted Critical
Publication of AU2001239551B8 publication Critical patent/AU2001239551B8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001239551A 2000-03-24 2001-03-23 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof Ceased AU2001239551B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19175500P 2000-03-24 2000-03-24
US60/191,755 2000-03-24
PCT/JP2001/002307 WO2001070233A2 (en) 2000-03-24 2001-03-23 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof

Publications (3)

Publication Number Publication Date
AU2001239551A1 AU2001239551A1 (en) 2001-12-13
AU2001239551B2 AU2001239551B2 (en) 2005-07-21
AU2001239551B8 true AU2001239551B8 (en) 2005-11-24

Family

ID=22706808

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001239551A Ceased AU2001239551B8 (en) 2000-03-24 2001-03-23 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
AU3955101A Pending AU3955101A (en) 2000-03-24 2001-03-23 Apoptosis inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU3955101A Pending AU3955101A (en) 2000-03-24 2001-03-23 Apoptosis inhibitor

Country Status (13)

Country Link
US (1) US7129272B2 (https=)
EP (1) EP1267882B1 (https=)
JP (1) JP2003527430A (https=)
KR (1) KR100788226B1 (https=)
CN (1) CN1443070A (https=)
AR (1) AR030275A1 (https=)
AT (1) ATE428429T1 (https=)
AU (2) AU2001239551B8 (https=)
CA (1) CA2403086C (https=)
DE (1) DE60138371D1 (https=)
NZ (1) NZ521464A (https=)
TW (1) TWI284535B (https=)
WO (1) WO2001070233A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1420794B1 (en) 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
CN1605336A (zh) 2003-10-10 2005-04-13 中国医学科学院药物研究所 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
US8202909B2 (en) * 2005-01-27 2012-06-19 Sucampo Ag Method for treating central nervous system disorders
WO2006106915A1 (ja) * 2005-03-31 2006-10-12 Asahi Glass Company, Limited プロスタグランジンＦ2α誘導体を有効成分として含む網膜神経細胞保護剤
JPWO2006112313A1 (ja) 2005-04-13 2008-12-11 宇部興産株式会社 インダゾール誘導体を有効成分として含む網膜神経細胞保護剤
EP1803809A3 (en) * 2005-08-12 2007-12-19 Abgenomics Corporation Modulation of peroxisome proliferator-activated receptors
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
SG193840A1 (en) * 2008-09-04 2013-10-30 Santen Pharmaceutical Co Ltd HAIR GROWTH PROMOTING AGENT CONTAINING 15,15-DIFLUOROPROSTAGLANDIN F2a DERIVATIVE AS ACTIVE INGREDIENT
US9084815B2 (en) 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0435443A2 (en) * 1989-11-22 1991-07-03 R-Tech Ueno Ltd. Use of 15-keto-prostaglandin compound for improvement of encephalic function
JPH08277222A (ja) * 1995-04-05 1996-10-22 Green Cross Corp:The 神経疾患の予防治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
DE3850676T2 (de) * 1987-09-18 1994-11-03 Ueno Seiyaku Oyo Kenkyujo Kk Hypotensive okulare Mittel.
JPH0761944B2 (ja) * 1989-11-22 1995-07-05 株式会社アールテック・ウエノ 脳機能改善処置剤
TW224942B (https=) 1990-04-04 1994-06-11 Adka Ueno Kk
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3625946B2 (ja) * 1995-03-10 2005-03-02 株式会社アールテック・ウエノ 視神経障害改善剤
JP3964060B2 (ja) * 1997-10-21 2007-08-22 独立行政法人科学技術振興機構 アポトーシス抑制剤
US6087395A (en) 1997-10-21 2000-07-11 Japan Science And Technology Corporation Isocarbacyclin derivatives as apoptosis inhibitors
JP2000169394A (ja) * 1998-12-04 2000-06-20 Yoshitomi Pharmaceut Ind Ltd アポトーシス誘導剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0435443A2 (en) * 1989-11-22 1991-07-03 R-Tech Ueno Ltd. Use of 15-keto-prostaglandin compound for improvement of encephalic function
JPH08277222A (ja) * 1995-04-05 1996-10-22 Green Cross Corp:The 神経疾患の予防治療剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Patents Abstract of Japan & JP 08277222 A *

Also Published As

Publication number Publication date
CA2403086A1 (en) 2001-09-27
CA2403086C (en) 2010-08-17
NZ521464A (en) 2004-09-24
CN1443070A (zh) 2003-09-17
TWI284535B (en) 2007-08-01
WO2001070233A3 (en) 2002-06-13
KR20020081474A (ko) 2002-10-26
JP2003527430A (ja) 2003-09-16
AR030275A1 (es) 2003-08-20
AU2001239551B2 (en) 2005-07-21
US7129272B2 (en) 2006-10-31
EP1267882B1 (en) 2009-04-15
AU3955101A (en) 2001-10-03
EP1267882A2 (en) 2003-01-02
ATE428429T1 (de) 2009-05-15
WO2001070233A2 (en) 2001-09-27
US20020025985A1 (en) 2002-02-28
KR100788226B1 (ko) 2007-12-26
DE60138371D1 (de) 2009-05-28

Similar Documents

Publication Publication Date Title
JP5073588B2 (ja) １５−ケトプロスタグランジンを含む胆汁分泌促進剤組成物
AU2001239551B8 (en) Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
KR20120045051A (ko) 복부 불쾌감 치료용 프로스타글랜딘의 유도체
AU2001239551A1 (en) Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
AU2001244727A2 (en) Bile secretion promoting composition
AU2001244727A1 (en) Bile secretion promoting composition
US20050014837A1 (en) Method for treating ocular hypertension and glaucoma
WO2010119986A1 (en) Method and composition for treating macular degeneration
JP4091132B2 (ja) 門脈圧亢進抑制剤
US20030060511A1 (en) Method for treatment of ocular hypertension and glaucoma
WO2003011178A2 (en) Method for treatment of ocular hypertension and glaucoma
JPWO1999018968A1 (ja) 門脈圧亢進抑制剤
US20040225014A1 (en) Method for treating ocular hypertension and glaucoma
US20030220396A1 (en) Method for treating ocular hypertension and glaucoma
AU2002326160A1 (en) Method and composition for treatment of ocular hypertension and glaucoma
AU2002255346A1 (en) Method for treatingocular hypertension and glaucoma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
TH Corrigenda

Free format text: IN VOL 19, NO 28, PAGE(S) 1888 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME SUCAMPO AG, APPLICATION NO. 2001239551, UNDER INID (54) CORRECT THE TITLE TO READ APOPTOSIS INHIBITING COMPOSITION COMPRISING A 15-KETO-PROSTAGLANDIN OR DERIVATIVE THEREOF

MK14 Patent ceased section 143(a) (annual fees not paid) or expired